For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the skyrizi industry by 2029?
The skyrizi market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to a rise in awareness of chronic inflammatory conditions, a rise in biosimilars, an increase in global healthcare access, an expansion of clinical indications, and a growth in long-term safety data.
The skyrizi market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growing adoption in psoriasis, increasing number of patients, growing geriatric population, increasing awareness and improved diagnosis, and increased consumption of processed foods. Major trends in the forecast period include technological innovations in biologics, a shift toward combination therapies, advancements in diagnostic technologies, a shift from oral to injectable treatments, and artificial intelligence (AI) for drug development.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp
Which industry-specific innovations are acting as key drivers for the skyrizi market?
The rising prevalence of psoriasis is expected to fuel the growth of the skyrizi market. Psoriasis refers to a chronic autoimmune condition that causes the rapid buildup of skin cells, leading to scaling on the skin’s surface. The rising prevalence of psoriasis is attributed to factors such as genetic predisposition, environmental triggers, increasing awareness and diagnosis rates, lifestyle changes, and the growing impact of stress and immune-related disorders on overall health. Skyrizi, a biologic therapy targeting interleukin-23 (IL-23), helps treat psoriasis by specifically blocking this cytokine, which plays a key role in the inflammatory process, thereby reducing skin inflammation, alleviating symptoms like redness and scaling, and improving overall skin clearance in patients with moderate to severe plaque psoriasis. For instance, in December 2022, according to the National Psoriasis Foundation (NPF), a US-based nonprofit organization, an estimated 8 million Americans and 125 million people worldwide (2-3% of the global population) have psoriasis. About 30% of those with psoriasis also develop psoriatic arthritis. Therefore, the rising prevalence of psoriasis drives the growth of skyrizi market.
Which segment currently leads the skyrizi market in terms of revenue share?
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Crohn’s Disease; Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes; Vials
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report
What future trends will impact the direction of the skyrizi industry?
A key trend in the skyrizi market is focusing on the expansion of therapeutic indications such as ulcerative colitis to enhance treatment outcomes for autoimmune diseases. Skyrizi is approved for treating moderate-to-severe ulcerative colitis (UC), showing significant clinical improvements in patients who have not responded to other treatments. For instance, in July 2024, AbbVie Inc., a US-based biopharmaceutical company, received European Commission approval for Skyrizi (risankizumab) for treating adult patients with moderately to severely active ulcerative colitis (UC) who have not responded to, or are intolerant to, conventional or biologic therapies. The approval is based on positive results from the Phase 3 INSPIRE and COMMAND trials, particularly showing mucosal healing in patients without prior biologic or JAK inhibitor use. Skyrizi’s dosing includes a 1,200 mg induction followed by 180 mg or 360 mg maintenance doses every 8 weeks.
Who are the top competitors in the global skyrizi market?
Major companies operating in the skyrizi market are AbbVie Inc.
What regional dynamics are shaping the future of the global skyrizi market?
North America was the largest region in the skyrizi market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Skyrizi Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20266
Need Customized Data On Skyrizi Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20266&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
